GSK's Exdensur Approved in the EU for Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps
EU Regulatory Approval Achieved
The European Union granted marketing authorization valid in all member states for GSK's Exdensur (depemokimab) on February 12, 2026. The approved indications are severe type 2 inflammatory asthma in patients 12 years and older whose condition is not adequately controlled with high-dose inhaled corticosteroids and additional controller medication, and severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose condition is not adequately controlled with systemic steroids or surgery. Following the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) on December 11, 2025, Exdensur has officially been approved and is now ready for commercialization in Europe.
Differentiated by Twice-Yearly Administration
The active ingredient in Exdensur, depemokimab, is a long-acting monoclonal antibody that blocks interleukin-5 (IL-5), which promotes the production and survival of eosinophils. Administered as a 100mg subcutaneous injection every 26 weeks, it differentiates itself from Nucala (mepolizumab, IL-5), Fasenra (benralizumab, IL-5 receptor alpha), Dupixent (dupilumab, IL-4 receptor alpha), and Tezspire (tezepelumab, TSLP), which are administered monthly. This less frequent dosing schedule can improve long-term adherence and reduce the burden of hospital visits, which are key factors for adoption in clinical practice.
Phase 3 Efficacy and the Boundary of Interpretation
The Phase 3 SWIFT-1 and SWIFT-2 trials for severe eosinophilic asthma included a total of 762 patients in the efficacy analysis, with annual exacerbation rates of 0.46 versus 1.11 for depemokimab and 0.56 versus 1.08 for placebo, respectively. The resulting exacerbation rate ratios were 0.42 and 0.52, both with p-values less than 0.001. However, it is important to note that the EMA also found that there was no significant improvement in health-related quality of life or lung function. In the two Phase 3 trials for CRSwNP, 540 patients were evaluated, and the mean nasal polyp score improved by 0.5 points in the Exdensur group after 52 weeks, while the placebo group showed a 0.1-point worsening, providing independent efficacy data to support both indications.
Market Potential and Global Regulatory Status
The five major European markets for severe asthma were valued at $825.1 million in 2023. Given that existing biologics have already established a strong presence, the success of Exdensur will depend on whether the twice-yearly administration translates into actual prescription conversions. The U.S. FDA approved Exdensur for severe eosinophilic asthma in patients 12 years and older on December 16, 2025, and approval for asthma and CRSwNP was also announced in Japan on December 22, 2025, significantly reducing regulatory risk in key markets. In Europe, health technology assessments (HTAs), pricing, and reimbursement negotiations in each member state will determine the speed of revenue conversion, and GSK will also need to manage potential cannibalization of its existing monthly IL-5 antibody, Nucala.
GSK has secured EU approval for Exdensur, following approvals in the U.S. and Japan, successfully transitioning it from a Phase 3 asset to a global commercial product. In the short term, the speed of national reimbursement listings and launches in the five major European markets, valued at $825.1 million in 2023 for severe asthma, will determine the revenue trajectory. In the medium to long term, the twice-yearly administration offers an advantage in adherence compared to Nucala, Fasenra, Dupixent, and Tezspire, but the lack of demonstrated improvement in quality of life and lung function may limit pricing power. From an R&D perspective, the 58% and 48% reductions in annual exacerbation rates in the SWIFT-1 and SWIFT-2 trials validate the clinical efficacy of long-acting IL-5 inhibition, and the simultaneous approval for CRSwNP expands the patient population and product lifecycle. While the reduction in regulatory risk and differentiated administration schedule are positive, we rate the investment outlook as Bullish, considering European pricing negotiations and the potential cannibalization of GSK's Nucala.
Source: EMA (ema)